BPF Genetics of ILD Study (BPF GILD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03747627|
Recruitment Status : Recruiting
First Posted : November 20, 2018
Last Update Posted : March 14, 2019
|Condition or disease||Intervention/treatment|
|Lung; Disease, Interstitial, With Fibrosis Alveolitis, Extrinsic Allergic Bird Fancier's Lung Idiopathic Interstitial Pneumonias Lung Diseases, Interstitial Idiopathic Pulmonary Fibrosis||Diagnostic Test: Genetic profiling|
The investigators aim to recruit participants with regular racing pigeon exposure at national (UK) and regional pigeon fancier meetings.
Consenting subjects will complete questionnaires, provide blood samples for genetic analysis and undertake lung function measurements.
Subjects will be observed, and encouraged to report referral to specialist respiratory services, and following this information will be sought on diagnosis (including supporting evidence). Where interstitial lung disease is detected this will be linked to subsequent unbiased analysis to detect potential predisposing genetic associations.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||600 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||British Pigeon Fanciers Genetics of Interstitial Lung Disease Study|
|Actual Study Start Date :||January 19, 2019|
|Estimated Primary Completion Date :||January 22, 2024|
|Estimated Study Completion Date :||January 1, 2028|
- Diagnostic Test: Genetic profiling
All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
- Relationship of specific genetic markers to development of interstitial lung disease [ Time Frame: 5 years ]Participants will be screened for MUC5B genetic profile to allow examination of MUC5B genetic profile relationship with risk of developing interstitial lung disease in this group
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03747627
|Contact: Mark Spears, PhD, FRCP||+44 firstname.lastname@example.org|
|Contact: Allyson Bailley, PhD||+44 email@example.com|
|Royal Pigeon Racing Association Meeting||Recruiting|
|Blackpool, United Kingdom, FY1 1HL|
|Contact: Mark Spears, PhD FRCP|
|Principal Investigator:||Mark Spears, PhD, FRCP||NHS Forth Valley|